Literature DB >> 9777183

Serum iron in catatonia and neuroleptic malignant syndrome.

J W Lee1.   

Abstract

BACKGROUND: Preliminary data suggest that decreased serum iron levels predict the progression of catatonia to neuroleptic malignant syndrome (NMS). This study examines the predictive value of low serum iron in this NMS conversion and explores other potential significance of serum iron in catatonia.
METHODS: Fifty patients with catatonia were prospectively identified at two psychiatric intensive care units during a 3-year period [incidence of 5% (39/716) and 13% (11/86) respectively]. Serum iron was measured in 39 episodes. Seventeen episodes (44%) showed low serum iron levels. A retrospective chart review of patients identified was conducted, comparing those with low and normal serum iron levels.
RESULTS: Low serum iron levels were associated with malignant catatonia, excited catatonia, and poor responses to benzodiazepines. There were 7 episodes of malignant catatonia. All had low serum iron. Neuroleptic were used in 5 of them, and all 5 evolved into NMS. No such NMS conversion was noted in those with normal serum iron or in nonmalignant catatonia with low serum iron. Seven episodes (with low serum iron) failing benzodiazepine therapy responded subsequently to lithium-neuroleptic combination therapy.
CONCLUSIONS: Malignant catatonia, associated with low serum iron, is at high risk of evolving into NMS. Low serum iron in nonmalignant catatonia does not predict this NMS conversion. Excited catatonia as a catatonic subtype (associated with low serum iron and unfavorable benzodiazepine responses) deserves more research attention. There appears to be a possible connection between treatment resistance to benzodiazepines, favorable responses to lithium-neuroleptic combination, and low serum iron.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9777183     DOI: 10.1016/s0006-3223(98)00109-7

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  21 in total

Review 1.  Neuroleptic malignant syndrome: a neuroimmunologic hypothesis.

Authors:  Rebecca E Anglin; Patricia I Rosebush; Michael F Mazurek
Journal:  CMAJ       Date:  2010-08-09       Impact factor: 8.262

2.  Atypical case of neuroleptic malignant syndrome caused by olanzapine and carbamazepine.

Authors:  Benjamin Kp Woo; Gabriela V Obrocea
Journal:  Psychiatry (Edgmont)       Date:  2005-12

3.  Catatonic schizophrenia: therapeutic challenges and potentially a new role for electroconvulsive therapy?

Authors:  Deirdre Philbin; D Mulryan; M O'Grady
Journal:  BMJ Case Rep       Date:  2013-07-29

Review 4.  [Malignant hyperthermia syndrome in the intensive care unit : Differential diagnosis and acute measures].

Authors:  W Grander
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-06-07       Impact factor: 0.840

5.  Management of common adverse effects of antipsychotic medications.

Authors:  T Scott Stroup; Neil Gray
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

Review 6.  Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis.

Authors:  Marco Solmi; G Giorgio Pigato; Beatrice Roiter; Argentina Guaglianone; Luca Martini; Michele Fornaro; Francesco Monaco; Andrè F Carvalho; Brendon Stubbs; Nicola Veronese; Christoph U Correll
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

7.  Systems genetic analysis of multivariate response to iron deficiency in mice.

Authors:  Lina Yin; Erica L Unger; Leslie C Jellen; Christopher J Earley; Richard P Allen; Ann Tomaszewicz; James C Fleet; Byron C Jones
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-03-28       Impact factor: 3.619

8.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

9.  Management and outcomes of catatonia: A prospective study in urban South Africa.

Authors:  Zukiswa Zingela; Louise Stroud; Johan Cronje; Max Fink; Stephan van Wyk
Journal:  SAGE Open Med       Date:  2022-06-20

Review 10.  Catatonia and its treatment.

Authors:  Patricia I Rosebush; Michael F Mazurek
Journal:  Schizophr Bull       Date:  2009-12-07       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.